Literature DB >> 28816505

Pre-attack signs and symptoms in cluster headache: Characteristics and time profile.

Agneta Snoer1, Nunu Lund1, Rasmus Beske1, Rigmor Jensen1, Mads Barloese1,2.   

Abstract

Introduction In contrast to the premonitory phase of migraine, little is known about the pre-attack (prodromal) phase of a cluster headache. We aimed to describe the nature, prevalence, and duration of pre-attack symptoms in cluster headache. Methods Eighty patients with episodic cluster headache or chronic cluster headache, according to ICHD-3 beta criteria, were invited to participate. In this observational study, patients underwent a semi-structured interview where they were asked about the presence of 31 symptoms/signs in relation to a typical cluster headache attack. Symptoms included previously reported cluster headache pre-attack symptoms, premonitory migraine symptoms and accompanying symptoms of migraine and cluster headache. Results Pre-attack symptoms were reported by 83.3% of patients, with an average of 4.25 (SD 3.9) per patient. Local and painful symptoms, occurring with a median of 10 minutes before attack, were reported by 70%. Local and painless symptoms and signs, occurring with a median of 10 minutes before attack, were reported by 43.8% and general symptoms, occurring with a median of 20 minutes before attack, were reported by 62.5% of patients. Apart from a dull/aching sensation in the attack area being significantly ( p < 0.05) more frequent among men and episodic patients, compared with women and chronic patients respectively, no other differences in the prevalence of pre-attack symptoms were identified between groups. Conclusion Pre-attack symptoms are frequent in cluster headache. Since the origin of cluster headache attacks is still unresolved, studies of pre-attack symptoms could contribute to the understanding of cluster headache pathophysiology. Furthermore, identification and recognition of pre-attack symptoms could potentially allow earlier abortive treatment.

Entities:  

Keywords:  Cluster headache; accompanying symptoms; pathophysiology; pre-attack symptoms; prodromes

Mesh:

Year:  2017        PMID: 28816505     DOI: 10.1177/0333102417726498

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  6 in total

1.  Hypothalamic regulation of headache and migraine.

Authors:  Arne May; Rami Burstein
Journal:  Cephalalgia       Date:  2019-08-29       Impact factor: 6.292

Review 2.  Exploring the Connection Between Sleep and Cluster Headache: A Narrative Review.

Authors:  Joseph V Pergolizzi; Peter Magnusson; Jo Ann LeQuang; Charles Wollmuth; Robert Taylor; Frank Breve
Journal:  Pain Ther       Date:  2020-05-07

3.  Cranial autonomic symptoms: prevalence, phenotype and laterality in migraine and two potentially new symptoms.

Authors:  Nazia Karsan; Karthik Nagaraj; Peter J Goadsby
Journal:  J Headache Pain       Date:  2022-01-29       Impact factor: 7.277

Review 4.  Pre-attack and pre-episode symptoms in cluster headache: a multicenter cross-sectional study of 327 Chinese patients.

Authors:  Ke Li; Shuping Sun; Zhanyou Xue; Sufen Chen; Chunyang Ju; Dongmei Hu; Xiaoyu Gao; Yanhong Wang; Dan Wang; Jianjun Chen; Li Li; Jing Liu; Mingjie Zhang; Zhihua Jia; Xun Han; Huanxian Liu; Mianwang He; Wei Zhao; Zihua Gong; Shuhua Zhang; Xiaoxue Lin; Yingyuan Liu; Shengshu Wang; Shengyuan Yu; Zhao Dong
Journal:  J Headache Pain       Date:  2022-07-30       Impact factor: 8.588

5.  Comprehensive clinical phenotyping of nitroglycerin infusion induced cluster headache attacks.

Authors:  Diana Y Wei; Peter J Goadsby
Journal:  Cephalalgia       Date:  2021-02-20       Impact factor: 6.292

6.  Evidence That HFE H63D Variant Is a Potential Disease Modifier in Cluster Headache.

Authors:  Maria Papasavva; Michail Vikelis; Martha-Spyridoula Katsarou; Vasileios Siokas; Emmanouil Dermitzakis; Christoforos Papademetriou; Konstantinos Karakostis; George Lazopoulos; Efthimios Dardiotis; Nikolaos Drakoulis
Journal:  J Mol Neurosci       Date:  2021-09-27       Impact factor: 3.444

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.